CDK6: An Emerging Target for Myelofibrosis Therapy and PROTAC-Based Detection Strategies

Author: Senior Product Manager of UA Views：9

This article systematically elucidates the pathological role of CDK6 in myelofibrosis and its potential as a therapeutic target. It highlights the upregulated expression of CDK6 in MPN/MF hematopoietic progenitor cells and its molecular mechanisms in driving myelofibrosis through the regulation of Aurora kinase, NF-κB, and TGF-β signaling pathways. The study also analyzes the efficacy validation of CDK4/6 inhibition strategies in MF models and explores the novel approach of CDK6-targeted degradation using CRBN-based PROTAC technology.

Recent Advances
Product Information

Recent Advances

CDK6: An Emerging Target for Myelofibrosis Therapy and PROTAC-Based Detection Strategies

Overview

This article systematically elaborates on the pathological role of CDK6 in myelofibrosis and its research progress as a therapeutic target. It details the upregulated expression of CDK6 in MPN/MF hematopoietic progenitor cells and its molecular mechanisms driving myelofibrosis through the regulation of Aurora kinase, NF-κB, and TGF-β signaling pathways. The efficacy validation of CDK4/6 inhibitor strategies in MF models is analyzed, and the novel approach of CDK6-targeted degradation via CRBN-based PROTAC technology is explored.

1. Disease Characteristics and Therapeutic Challenges of Myelofibrosis

Myelofibrosis is the most aggressive form of myeloproliferative neoplasms, characterized by bone marrow fibrosis, leukocytosis, and extramedullary hematopoiesis. The median survival of MF patients with intermediate- or high-risk disease ranges from 16 to 35 months, indicating a very poor prognosis. The oncogenic JAK2V617F mutation is detectable in 50% to 60% of MF patients. Additionally, mutations in the thrombopoietin receptor and calreticulin are observed in MF. JAK2, MPL, and CALR mutations are considered driver mutations in MPN, leading to hyperactivation of JAK/STAT signaling.

Currently approved JAK inhibitors can alleviate symptoms but do not cure or significantly improve bone marrow fibrosis in MF patients. Moreover, in many cases, initial therapeutic responses diminish after long-term treatment. Therefore, there is an urgent need to develop novel MF treatments that can effectively address myelofibrosis. This clinical dilemma has driven researchers to explore other key molecules in the pathogenesis of MF, bringing CDK6 into focus.

2. Pathological Role of CDK6 in Hematologic Malignancies

Cyclin-dependent kinase 6 (CDK6) and its close homolog CDK4 regulate the G1-to-S phase cell cycle progression by activating the CDK4/6-cyclin D complex and subsequent phosphorylation of retinoblastoma protein, thereby driving E2F-dependent transcription. Mice lacking Cdk6 are viable, exhibiting only minor defects in erythrocyte and thymocyte development. CDK6 is upregulated in various hematologic malignancies. It is essential for leukemia development mediated by MLL- and NUP98-fusion oncoproteins. CDK6 can also function as a transcriptional regulator, with both kinase-dependent and kinase-independent roles proposed.

Studies show that CDK6 can interact with the NF-κB subunit p65 and serve as a transcriptional co-regulator of NF-κB-dependent gene expression. Inhibitors targeting CDK4/6 have been developed and tested in various human cancers, with three CDK4/6 inhibitors approved for treating hormone receptor-positive advanced breast cancer. The potential applications of these inhibitors in hematologic malignancies are being actively explored.

3. Functional Validation of CDK6 in Myelofibrosis Models

Research has found that CDK6 expression is significantly elevated in hematopoietic progenitor cells from Jak2V617F knock-in mice and MF patients. In Jak2V617F and MPLW515L mouse MF models, monotherapy with CDK4/6 inhibitors markedly reduced leukocytosis and splenomegaly and suppressed bone marrow fibrosis. Combination therapy with CDK4/6 inhibitors and JAK inhibitors normalized peripheral blood leukocyte counts, significantly reduced spleen size, and eliminated bone marrow fibrosis in MF model mice.

CDK4/6 inhibitor treatment also preferentially inhibited Jak2V617F-mutant hematopoietic progenitor cells in mice. Mechanistically, CDK4/6 inhibitor treatment or CDK6 deletion suppressed Aurora kinase, NF-κB, and TGF-β signaling pathways in Jak2V617F-mutant hematopoietic cells and attenuated the expression of fibrosis markers in the bone marrow. TGF-β1 stimulation significantly increased type I and III collagen expression in bone marrow mesenchymal stem cells, and CDK6 inhibition blocked this fibrotic process by disrupting TGF-β signaling. Collectively, these data suggest that CDK6-targeted inhibition combined with JAK inhibition may have therapeutic potential for MF and support clinical studies of this combination strategy.

4. PROTAC Technology: A Novel Approach for CDK6-Targeted Degradation

Proteolysis-targeting chimeras (PROTACs) utilize the ubiquitin-proteasome system to direct target proteins to the proteasome for degradation. Unlike traditional small-molecule inhibitors that block protein function by occupying active sites, PROTAC molecules form a ternary complex (target protein-PROTAC-E3 ligase) by binding the target protein at one end and recruiting an E3 ligase at the other, mediating polyubiquitination and subsequent proteasomal degradation of the target protein.

For the CDK6 target, PROTAC technology offers a degradation strategy independent of kinase activity inhibition. CDK6 has both kinase-dependent functions and kinase-independent roles as a transcriptional regulator. Traditional CDK4/6 inhibitors primarily target its kinase activity, whereas PROTACs can completely eliminate both kinase-dependent and kinase-independent functions by degrading CDK6 protein. CRBN-based PROTAC molecules recruit the CRBN E3 ligase to achieve targeted degradation of CDK6, showing promise in preclinical studies of hematologic malignancies. The ability to form ternary complexes is a critical parameter determining PROTAC degradation efficiency, making the establishment of high-efficiency and reliable binding assays essential at this stage.

5. Conclusion

In practical applications of CDK6-targeted degradation research, high-quality binding assay reagents are crucial for ensuring data reliability and experimental reproducibility. To meet the needs of CDK6/CRBN PROTAC ternary complex evaluation, UniOne® provides the TR-FRET Human CDK6/CRBN PROTAC Binding Kit. This product, based on TR-FRET detection technology, features the following core characteristics: long fluorescence lifetime of lanthanide donors reduces background interference through time-resolved detection; homogeneous operation mode requires no washing or separation steps and is compatible with high-throughput formats (96- and 384-well plates); stable signals support batch processing and flexible time windows; and quantitative detection of PROTAC-induced ternary complex formation between CDK6 and CRBN. This kit is suitable for screening and ranking PROTAC molecules' bridging activity, linker optimization, structure-activity relationship analysis, and CRBN ligand selectivity evaluation.

CDK6, as an emerging target for myelofibrosis therapy, has been gradually elucidated in its molecular mechanisms driving myelofibrosis through the regulation of Aurora kinase, NF-κB, and TGF-β signaling pathways. The significant efficacy of CDK4/6 inhibition combined with JAK inhibition in MPN/MF mouse models provides a new strategic direction for combination therapy in myelofibrosis. Meanwhile, CRBN-based PROTAC technology, by inducing selective degradation of CDK6 protein, offers a novel intervention approach to completely eliminate both kinase-dependent and kinase-independent functions of CDK6. The UniOne® TR-FRET Human CDK6/CRBN PROTAC Binding Kit provides a reliable tool for binding assays of CDK6-targeted PROTAC molecules, continuously driving innovation in the field of targeted therapy for myelofibrosis.

```

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next